Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?

Jonathan R Strosberg; Ghassan El-Haddad; Taymeyah Al-Toubah; Diane Reidy; Etay Ziv; Armeen Mahvash; Arvind Dasari; Philip Philip; Michael C Soulen

doi:10.2967/jnumed.121.263041

Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?

J Nucl Med. 2021 Sep 23;62(12):1669-1671. doi: 10.2967/jnumed.121.263041. Online ahead of print.

Authors

Jonathan R Strosberg¹, Ghassan El-Haddad², Taymeyah Al-Toubah¹, Diane Reidy³, Etay Ziv⁴, Armeen Mahvash⁵, Arvind Dasari⁵, Philip Philip⁶, Michael C Soulen⁷

Affiliations

¹ H. Lee Moffitt Cancer Center & Research Institute.
² H. Lee Moffitt Cancer Center and Research Institute.
³ Memorial Sloan-Kettering Cancer Center.
⁴ MSKCC.
⁵ MD Anderson Cancer Center.
⁶ Karmanos Cancer Center.
⁷ University of Pennsylvania.

No abstract available

Keywords: Gastrointestinal; Neuroendocrine; Neuroendocrine tumors; Radiopharmaceuticals; liver metastases; transarterial chemoembolization; transarterial embolization; transarterial radioembolization.